<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00285623</url>
  </required_header>
  <id_info>
    <org_study_id>TC-018-IN</org_study_id>
    <nct_id>NCT00285623</nct_id>
  </id_info>
  <brief_title>Observational Cohort Study of TachoSil (TC-018-IN)</brief_title>
  <official_title>An Non-interventional, Prospective, Non-controlled Study of the Use of TachoSil in Supportive Treatment in Surgery for Improvement of Haemostasis Where Standard Techniques Are Insufficient.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nycomed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nycomed</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect information, after exposure to TachoSil 速, of all
      thromboembolic events, immunological events and drug interactions leading to thromboembolic
      events or major bleeding. In addition, pharmacoeconomic data will be collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">3000</enrollment>
  <condition>Blood Loss, Surgical</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrinogen (human) + thrombin (human) (TachoSil)</intervention_name>
    <description>treatment in surgery for improvement of haemostasis where standard techniques are insufficient</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients exposed to TachoSil速 of all thromboembolic events, immunological events and drug
        interactions leading to thromboembolic events or major bleeding.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects, treated with TachoSil 速 by the participating physicians, will be
             registered with a set of basic data from their already existing data (i.e. no
             additional diagnostic procedures will be performed).

          -  Subjects who will provide their written informed consent to use existing data, allow
             direct access to data and data processing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nycomed Clinical Trial Operations</last_name>
    <role>Study Chair</role>
    <affiliation>Headquarters</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2005</study_first_submitted>
  <study_first_submitted_qc>February 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2006</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <name_title>Nycomed</name_title>
    <organization>Clinical Trial Operations</organization>
  </responsible_party>
  <keyword>Collection of all thromboembolic events,</keyword>
  <keyword>immunological events and drug interactions leading to thromboembolic events or major</keyword>
  <keyword>bleeding after exposure to TachoSil速.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

